Madrigal Pharmaceuticals Financials - Benzinga

Madrigal Pharmaceuticals Inc

MDGLNASDAQ

Trade with Public

Trade with Public

$531.52

-2.88-0.54%

At close: Sep 18, 5:00 PM EST

$531.52

N/A

After Hours: 4:04 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Madrigal Pharmaceuticals Financials

Madrigal Pharmaceuticals (MDGL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M Estimate

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.50) by 20.4 percent. This is a 4.74 percent decrease over losses of $(1.90) per

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Madrigal Pharmaceuticals Q1 EPS $(3.25) Beats $(3.60) Estimate, Sales $311.337M Beat $302.268M Estimate

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.25) per share which beat the analyst consensus estimate of $(3.60) by 9.72 percent. This is a 24.52 percent decrease over losses of $(2.61) per

Benzinga Newsdesk

PRO
Madrigal Pharmaceuticals Q4 2025 EPS $(2.57) Misses $(0.40) Estimate, Sales $321.083M Beat $312.490M Estimate

Benzinga Newsdesk

Earnings Scheduled For February 19, 2026

Benzinga Insights

Earnings Preview For Madrigal Pharmaceuticals

Benzinga Insights